Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › Biocartis, Nichirei Bioscience Ink Commercialization Agreement for Japan

Biocartis, Nichirei Bioscience Ink Commercialization Agreement for Japan

Jan 07, 2019

NEW YORK (GenomeWeb) – Biocartis announced today it has signed a commercialization agreement with Nichirei Bioscience, a supplier of biological and diagnostics products in Japan.

Financial terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Feb
23
Featured Webinar

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Feb
24
Featured Webinar

Case Study: Rapid Development and Manufacturing Scaleup of a Point-of-Care COVID-19 Test

Sponsored by
SCHOTT MINIFAB

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints. 

What's Popular?

In PCR

  1. At JP Morgan Conference, Quidel CEO Discusses Plan to Enter OTC Infectious Disease Test Market

  2. FDA Grants Emergency Use Authorization for SML Genetree Molecular Coronavirus Test

  3. BARDA Provides Additional Funding to DiaSorin Molecular for COVID-19 Tests

  4. Becton Dickinson Preliminary Fiscal Q1 Revenues Rise 26 Percent, Firm Raises Guidance

  5. Invitae, Pharma Firms Partner to Develop Standard MRD Panel for AML Clinical Trials

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.